WINLEVI Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Winlevi patents expire, and when can generic versions of Winlevi launch?
Winlevi is a drug marketed by Sun Pharm and is included in one NDA. There are eight patents protecting this drug.
This drug has eighty-nine patent family members in twenty-six countries.
The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this compound. Additional details are available on the clascoterone profile page.
DrugPatentWatch® Generic Entry Outlook for Winlevi
Winlevi will be eligible for patent challenges on August 26, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 25, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for WINLEVI
| International Patents: | 89 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Patent Applications: | 93 |
| What excipients (inactive ingredients) are in WINLEVI? | WINLEVI excipients list |
| DailyMed Link: | WINLEVI at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for WINLEVI
Generic Entry Date for WINLEVI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CREAM;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for WINLEVI
| Drug Class | Androgen Receptor Inhibitor |
| Mechanism of Action | Androgen Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for WINLEVI
US Patents and Regulatory Information for WINLEVI
WINLEVI is protected by eight US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of WINLEVI is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting WINLEVI
Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE
Enzymatic process for obtaining 17 .alpha.-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17ALPHA-PROPIONATE
17.alpha., 21-dihydroxypregnene esters as antiandrogenic agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE
Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE
17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Enzymatic process for obtaining 17.alpha.-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE
FDA Regulatory Exclusivity protecting WINLEVI
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | WINLEVI | clascoterone | CREAM;TOPICAL | 213433-001 | Aug 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Sun Pharm | WINLEVI | clascoterone | CREAM;TOPICAL | 213433-001 | Aug 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Sun Pharm | WINLEVI | clascoterone | CREAM;TOPICAL | 213433-001 | Aug 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Sun Pharm | WINLEVI | clascoterone | CREAM;TOPICAL | 213433-001 | Aug 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Sun Pharm | WINLEVI | clascoterone | CREAM;TOPICAL | 213433-001 | Aug 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for WINLEVI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sun Pharm | WINLEVI | clascoterone | CREAM;TOPICAL | 213433-001 | Aug 26, 2020 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for WINLEVI
When does loss-of-exclusivity occur for WINLEVI?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 2235
Estimated Expiration: See Plans and Pricing
Patent: 1202
Estimated Expiration: See Plans and Pricing
Patent: 1351
Estimated Expiration: See Plans and Pricing
Australia
Patent: 08285784
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 0814163
Estimated Expiration: See Plans and Pricing
Canada
Patent: 91445
Estimated Expiration: See Plans and Pricing
Patent: 71025
Estimated Expiration: See Plans and Pricing
Patent: 71039
Estimated Expiration: See Plans and Pricing
China
Patent: 1743316
Estimated Expiration: See Plans and Pricing
Patent: 3450304
Estimated Expiration: See Plans and Pricing
Patent: 4861023
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0140421
Estimated Expiration: See Plans and Pricing
Patent: 0151174
Estimated Expiration: See Plans and Pricing
Patent: 0151298
Estimated Expiration: See Plans and Pricing
Patent: 0191143
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 73891
Estimated Expiration: See Plans and Pricing
Patent: 03004
Estimated Expiration: See Plans and Pricing
Patent: 03005
Estimated Expiration: See Plans and Pricing
Patent: 66175
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 73891
Estimated Expiration: See Plans and Pricing
Patent: 03004
Estimated Expiration: See Plans and Pricing
Patent: 03005
Estimated Expiration: See Plans and Pricing
Patent: 66175
Estimated Expiration: See Plans and Pricing
Patent: 21298
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 26206
Estimated Expiration: See Plans and Pricing
Patent: 26507
Estimated Expiration: See Plans and Pricing
Patent: 44237
Estimated Expiration: See Plans and Pricing
Italy
Patent: 20071616
Estimated Expiration: See Plans and Pricing
Japan
Patent: 46992
Estimated Expiration: See Plans and Pricing
Patent: 08944
Estimated Expiration: See Plans and Pricing
Patent: 74645
Estimated Expiration: See Plans and Pricing
Patent: 10535173
Estimated Expiration: See Plans and Pricing
Patent: 13163683
Estimated Expiration: See Plans and Pricing
Patent: 16014045
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 66175
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 3238
Estimated Expiration: See Plans and Pricing
Patent: 3701
Estimated Expiration: See Plans and Pricing
Patent: 10001256
Estimated Expiration: See Plans and Pricing
Patent: 19003639
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 9437
Estimated Expiration: See Plans and Pricing
Patent: 0767
Estimated Expiration: See Plans and Pricing
Patent: 5953
Estimated Expiration: See Plans and Pricing
Poland
Patent: 73891
Estimated Expiration: See Plans and Pricing
Patent: 03004
Estimated Expiration: See Plans and Pricing
Patent: 03005
Estimated Expiration: See Plans and Pricing
Patent: 66175
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 73891
Estimated Expiration: See Plans and Pricing
Patent: 03004
Estimated Expiration: See Plans and Pricing
Patent: 03005
Estimated Expiration: See Plans and Pricing
Patent: 66175
Estimated Expiration: See Plans and Pricing
Russian Federation
Patent: 82190
Estimated Expiration: See Plans and Pricing
Patent: 99452
Estimated Expiration: See Plans and Pricing
Patent: 10107599
Estimated Expiration: See Plans and Pricing
Patent: 12113839
Estimated Expiration: See Plans and Pricing
Serbia
Patent: 310
Estimated Expiration: See Plans and Pricing
Patent: 354
Estimated Expiration: See Plans and Pricing
Patent: 361
Estimated Expiration: See Plans and Pricing
Patent: 950
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 73891
Estimated Expiration: See Plans and Pricing
Patent: 03004
Estimated Expiration: See Plans and Pricing
Patent: 03005
Estimated Expiration: See Plans and Pricing
Patent: 66175
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1000587
Estimated Expiration: See Plans and Pricing
Patent: 1100133
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1495192
Estimated Expiration: See Plans and Pricing
Patent: 100044845
Estimated Expiration: See Plans and Pricing
Spain
Patent: 62946
Estimated Expiration: See Plans and Pricing
Patent: 51910
Estimated Expiration: See Plans and Pricing
Patent: 54934
Estimated Expiration: See Plans and Pricing
Patent: 32326
Estimated Expiration: See Plans and Pricing
Turkey
Patent: 1909129
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering WINLEVI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2462946 | See Plans and Pricing | |
| European Patent Office | 3521298 | FORME CRISTALLINE III DE CORTEXOLONE-17-ALPHA-PROPIONATE ET SON UTILISATION PHARMACEUTIQUE (CORTEXOLONE-17-ALPHA-PROPIONATE CRYSTALLINE FORM III AND ITS PHARMACEUTICAL USE) | See Plans and Pricing |
| Poland | 2503005 | See Plans and Pricing | |
| New Zealand | 615953 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | See Plans and Pricing |
| Croatia | P20151174 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
